ClinicalTrials.gg
WithdrawnNCT03338881Updated Feb 8, 2023

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

A Phase 1 interventional study of [14C]-TAK-659 and TAK-659 in Advanced Solid Neoplasms and Lymphoma Neoplasms, sponsored by Calithera Biosciences, Inc. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other

Why this study was withdrawn
Business decision: no safety or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659 solution containing 60 to 80 micro curie (Ci) of total radioactivity in participants with advanced solid tumors and/or lymphomas.

Read the detailed description

The drug being tested in this study is called TAK-659. TAK-659 is being tested to treat people who have advanced solid tumor and/or lymphoma malignancies. This study will look at the quantitative characterization of the mass balance, metabolic pathways, and rates and routes of excretion of TAK-659.

The study will enroll approximately 6 participants. The study will consist of 2 periods: absorption, distribution, metabolism, and excretion (ADME) study period and optional post-ADME study period. In ADME study period, participants will be assigned with [14C]-TAK-659 100 milligram (mg). After completion of ADME study period, participants may choose to continue in the optional post-ADME study period to receive TAK-659 100 mg.

This single center trial will be conducted in Netherlands. The overall time to participate in ADME study period will be 14 days and if participants choose the option to continue in the post-ADME study period, the maximum duration of participation will be 12 months, unless in the opinion of the investigator and sponsor the participant would derive benefit from continued treatment beyond 12 months. Participants will be followed up to 28 days after last dose of study drug or until the start of subsequent antineoplastic therapy, whichever occurs first.

02

Conditions studied

  • Advanced Solid Neoplasms
  • Lymphoma Neoplasms

Keywords

  • Drug therapy
03

In context

Lead sponsor

Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must have or cytologically confirmed and/or advanced solid tumors and/or lymphomas for which standard curative or life-prolonging treatment does not exist or is no longer effective or tolerable.
  2. (ECOG) performance status score of 0 or 1.
  3. of at least 3 months.
  4. Suitable venous access for the study-required blood sampling (that is, PK).
  5. Recovered (that is, grade less than or equal to [\<=] 1 toxicity) from the reversible effects of prior anticancer therapy (with the exception of alopecia and Grade 1 neuropathy).
  6. Must have adequate organ function, including the following:

    • Adequate bone marrow reserve: (ANC) greater than or equal to (>=) 1000 per microliter (/mcL); count >=75,000/mcL (>=50,000/mcL for participants with bone marrow involvement); and >=8 gram per deciliter (g/dL) (red blood cell [RBC] and platelet transfusion allowed >=14 days before assessment).
    • Hepatic: total \<=1.5 times the (ULN); (ALT) and aspartate aminotransferase (AST) \<=2.5*ULN.
    • Renal: >=60 milliliter per minute (mL/min) either as estimated by the Cockcroft-Gault equation or based on urine collection

Key Exclusion Criteria:

  1. Central nervous system (CNS) lymphoma; active brain or , as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
  2. Known (HIV) positivity or HIV-related .
  3. Systemic anticancer treatment (including agents) or radiotherapy within 3 weeks before the first dose of study treatment \<=5 times the half-life for large molecule agents or \<=4 weeks with evidence of progressive disease if 5 times the half-life is greater than (>) 4 weeks.
  4. Use or consumption of any of the following substances:

    • Medications or supplements that are known to be inhibitors of P-glycoprotein (P-gp) and/or strong reversible inhibitors of cytochrome P450 (CYP) 3A within 5 times the inhibitor half-life (if a reasonable half-life estimate is known), or within 7 days (if a reasonable half-life estimate is unknown), before the first dose of study drugs
    • Medications or supplements that are known to be strong mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days or within 5 times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drugs. In general, the use of these agents is not permitted during the study except when an AE must be managed during interruption of study drug dosing.
    • Food or beverages containing grapefruit within 5 days before the first dose of study drugs. Note that food and beverages containing grapefruit are not permitted during the study.
  5. Ongoing nausea or vomiting that is Grade 2 or worse in intensity.
  6. Systemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
  7. Active secondary malignancy that requires treatment. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.
  8. Irregular defecation patterns and/or history of urinary and/or fecal incontinence.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    [14C]-TAK-659 100 mg

    \[14C\]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.

    Drug: [14C]-TAK-659 · Drug: TAK-659

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  2. Cmax: Maximum Observed Plasma and Whole Blood Radioactivity for [14C]-TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  4. Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  5. AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  6. AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve from Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-659

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  7. Ae urine,14C: Cumulative Amount of Radioactivity Excreted in Urine for [14C]-TAK-659

    Time frame: Baseline up to 14 days

  8. Ae feces, 14C: Cumulative Amount of Radioactivity Excreted in Feces for [14C]-TAK-659

    Time frame: Baseline up to 14 days

  9. Ae total: Total Cumulative Amount of Radioactivity Excreted in Urine and Feces for [14C]-TAK-659

    Time frame: Baseline up to 14 days

  10. Ae urine: Cumulative Amount of TAK-659 Excreted in Urine

    Time frame: Baseline up to 14 days

  11. Percentage of Dose Excreted in Urine for TAK-659

    Time frame: Baseline up to 14 days

  12. Renal Clearance (CLR) of TAK-659

    Time frame: Baseline up to 14 days

Secondary outcomes

  1. Percentage of TAK-659 Metabolites in Plasma

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

  2. Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  3. Percentage of Participants with Grade 3 or Higher Adverse Events (AEs)

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  4. Percentage of Participants with Drug Related AEs

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  5. Percentage of Participants with Drug Related Grade 3 or Higher AEs

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  6. Percentage of Participants with AEs Leading to Discontinuation of TAK-659

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  7. Percentage of Participants who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  8. Percentage of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose

    Time frame: Baseline up to 28 days after the last dose of study drug (Week 58)

  9. Percentage of TAK-659 Metabolites in Urine and Feces

    Time frame: Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2018; primary completion for May 2019, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 9, 2017
StartEst.
May 10, 2018
Primary completionEst.
May 1, 2019
CompletionEst.
May 1, 2019
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03338881
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
May 10, 2018 (estimated)
Primary completion
May 1, 2019 (estimated)
Completion
May 1, 2019 (estimated)
Last update
Feb 8, 2023

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-659

Start the discussion